TrialEndocrinology, diabetes & metabolism2021
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
Brian Baker et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this paperpooled ittrialcites it